Johnson & Johnson (JNJ)

AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.

The next bear market may be your best opportunity to grow your portfolio.

Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.

Wall Street thinks that this robotic surgical systems leader's sell-off is overdone.

You can take these companies' dividends straight to the bank.

Healthcare giant Johnson & Johnson is looking to become a more profitable and faster-growing business.

It may not be possible to avoid all risks, but it's certainly possible to minimize them.

The unlocking of SpaceX shares is reshaping the communications sector.

One healthcare dividend payer carries legal risk, the other faces a buyout. Here's which one actually deserves your money.

Johnson & Johnson (NYSE:JNJ) Executive Vice President and Chief Financial Officer Joe Wolk said the company sees a path to growth above its previously stated 5% to 7% long-term range, supported by its pharmaceutical pipeline, medical technology portfolio and capital flexibility. Speaking at a Deuts

As Fed and inflation worries mount, Casey's General Stores, Johnson & Johnson, and PepsiCo stand out as defensive dividend payers with healthy balance sheets, growing payouts, and buyback programs.

It is certainly a good Dividend King to buy in September.

These players offer a certain level of stability in any market environment.

Healthcare stocks Eli Lilly, UnitedHealth Group, and Johnson & Johnson offer options for investors of different ages, combining growth potential, turnaround momentum, and reliable dividends.